NewEdge Advisors LLC Acquires 5,761 Shares of IDEXX Laboratories, Inc. $IDXX

NewEdge Advisors LLC lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 60.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,221 shares of the company’s stock after buying an additional 5,761 shares during the quarter. NewEdge Advisors LLC’s holdings in IDEXX Laboratories were worth $8,552,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. KBC Group NV raised its position in shares of IDEXX Laboratories by 76.9% in the 4th quarter. KBC Group NV now owns 309,380 shares of the company’s stock valued at $209,305,000 after acquiring an additional 134,493 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its holdings in IDEXX Laboratories by 4.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 209,106 shares of the company’s stock valued at $141,466,000 after purchasing an additional 8,626 shares during the period. Elyxium Wealth LLC bought a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $3,666,459,000. NewEdge Wealth LLC increased its stake in IDEXX Laboratories by 122.3% in the fourth quarter. NewEdge Wealth LLC now owns 6,597 shares of the company’s stock valued at $4,463,000 after purchasing an additional 3,629 shares in the last quarter. Finally, Prospera Financial Services Inc acquired a new stake in IDEXX Laboratories in the fourth quarter worth $4,188,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

IDXX opened at $586.67 on Monday. The stock has a market capitalization of $46.22 billion, a P/E ratio of 41.26, a P/E/G ratio of 3.18 and a beta of 1.54. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98. The firm’s fifty day simple moving average is $559.73 and its 200 day simple moving average is $584.88. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The firm had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company’s revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on IDXX shares. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. UBS Group lifted their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Finally, Citigroup increased their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $756.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.